Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
In 2024, a group of Southeast L.A. residents filed a lawsuit against Sterigenics, a company that uses a controversial ...
Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.
According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1% ...
7d
Notable healthcare headlines for the week: UnitedHealth, Boston Scientific, and Eli Lilly in focus
The 80-week trial reached the primary and key secondary endpoints, the Indiana-based drugmaker said, noting that those taking retatrutide 9 mg and 12 mg witnessed an average weight loss of 26% and 28% ...
Transcatheter aortic valve replacement (TAVR) with a self-expanding valve still worked out better, at least in terms of ...
An 86-year-old woman from Iowa became the first person in Nebraska to undergo a new heart valve replacement procedure, ...
Clinical event rates were still no different with longer follow-up, but one investigator thinks an advantage will emerge in ...
Joseph Walker is a New York-based reporter covering the biotechnology and medical device industries.
EmStop has initiated the CAPTURE-2 IDE clinical trial to support the firm’s mission to develop an embolic protection system ...
The move could revive a closely watched case with significant implications for how litigants frame claims and quantify ...
Anteris Technologies Global (ASX:AVR) recorded its first quarter for 2026, headlined by a US$320 million aggregate capital raise in January that has de-risked the commercial pathway for its flagship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results